Extracellular ATP and adenosine activate specific receptors on host and tumor cells.
Host adenosine (A2A) receptor activation causes immunosuppression.
Host adenosine (A2A) receptor blockade inhibits tumor growth.
Most tumors overexpress selected ATP receptor subtypes, namely P2X7.
Pre-clinical data show that P2X7 targeting has a potent anti-tumor effect.